FDA Import Refusal SCS-1999474-0/11/1 — Glaxosmithkline
The FDA refused shipment SCS-1999474-0/11/1 from Glaxosmithkline (Philippines) on Oct 14, 2020. The refused product falls under Drugs and Biologics — INSULIN (INJ) (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal details
- Date
- Oct 14, 2020
- Country
- Philippines
- Product Category
- Drugs and Biologics
- Product Code
- 61PCP17 INSULIN (INJ) (ANTI-DIABETIC)
- Charges
- 75